A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.06.10.21258709: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Informed consent was obtained from the participants to admit the study. Sex as a biological variable not detected. Randomization Study design: This pilot randomized controlled open label study was conducted at Alkarkh and Alforat hospitals in Baghdad city from January 2021-to April 2021. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Protocol of therapy: Outcome Measurements: Statistical analysis: Data was processed using SPSS version 13.1 and Microsoft Excel version 10.0.2. SPSSsuggested: (SPSS, RRID:SCR_002865)Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also …
SciScore for 10.1101/2021.06.10.21258709: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Informed consent was obtained from the participants to admit the study. Sex as a biological variable not detected. Randomization Study design: This pilot randomized controlled open label study was conducted at Alkarkh and Alforat hospitals in Baghdad city from January 2021-to April 2021. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Protocol of therapy: Outcome Measurements: Statistical analysis: Data was processed using SPSS version 13.1 and Microsoft Excel version 10.0.2. SPSSsuggested: (SPSS, RRID:SCR_002865)Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has some limitations: first, open label study with short time ; second, small sample size and done in single center, However this study, up to the best of our knowledge, was the first study that evaluated NCS effectiveness and safety as add on therapy to the standard care of measures in COVID-19 patients. In conclusion, this study showed that adding NCS to the standards of care measures had shorter time to stay in the hospital compared with controls especially for patients with moderate and severe COVID-19 who had comorbidities.. In addition, it was relatively safe without observable adverse events. These findings may suggest using NCS as an add on therapy to protocols used for treatment of COVID-19. However, these results are needed to be validated in a larger prospective follow up study.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04753619 Recruiting Effectiveness of Niclosamide as Add-on Therapy to the Standa… Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
